The invention relates to a novel coronavirus inactivating agent in the form of miramistine (alias myristamide-propyl-dimethyl-benzyl-ammonium chloride) previously known as anticeptic which exhibits antimycotic and antimicrobial actions and is efficient against HIV, influenza and herpes virus infections. Said invention extends a range of agents for said uses and makes it possible to treat and prevent respiratory tract diseases (including SARS) and gastro-enteritis provoked by said coronaviruses
